Movement Alert｜EVEREST MED Intraday Rise 5.5% in Regular Trading, mRNA Global Clinical Development Expectations Continue to Build

Market Focus10-20

On October 20, EVEREST MED rose 5.5% in regular trading, trading at HK$34.1, with turnover of HK$139 million.

The move aligns with continued market focus on the company’s mRNA platform after it brought in two former Moderna core scientists, a development that has been repeatedly cited in recent market coverage as supporting expectations for faster global clinical development.

Background disclosures show the new appointments are intended to advance the company’s mRNA platform clinical development in the United States in coordination with its China R&D team. The company has also disclosed that personalized therapeutic cancer vaccine EVM16 has produced initial human data, while off-the-shelf tumor-associated antigen vaccine EVM14 is advancing in clinical development, reinforcing investor attention on its platform entering a clinical validation stage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment